Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma
1998
Background: Weekly alternating regimen known as CAPOMEt
is compared to standard cyclical chemotherapy (CHOP-Mtx)
in aggressive non-Hodgkin's lymphoma (NHL).
Patients and methods: Three hundred and eighty-one patients
with aggressive NHL were randomised to receive either cyclophosphamide,
doxorubicin, vincristine, prednisone and methotrexate
(CHOP-Mtx) on a cyclical basis or a weekly regimen
incorporating the same drugs with the addition of etoposide
(CAPOMEt).
Results: After pathological review, 281 patients were deemed
eligible. At the census date of 31 March 1994, 158 patients were
alive with a median follow up of 5.9 years (minimum 3.0 years).
Analysis of all patients and eligible patients showed no significant
treatment differences in the rates of complete remission
(CR), failure free survival (FFS) or overall survival (OS) between
the two arms. The actuarial median OS was 24 months
for CAPOMEt compared with 31 months for CHOP-Mtx,
with five-year actuarial survival rates of 37% and 43%, respectively.
Myelosuppression was significantly more severe with
CHOP-Mtx and neurotoxicity was much more common with
CAPOMEt.
Conclusion: Weekly CAPOMEt is equally effective as standard
cyclical CHOP-Mtx treatment in aggressive NHL.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
17
References
9
Citations
NaN
KQI